Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free TTOO Stock Alerts

T2 Biosystems (TTOO) Competitors

T2 Biosystems logo
$0.0020 0.00 (0.00%)
As of 07/2/2026
Compare

TTOO vs. SDCCQ, GMVDF, VRAYQ, AFIB, and UTRS

Should you buy T2 Biosystems stock or one of its competitors? MarketBeat compares T2 Biosystems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with T2 Biosystems include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "medical equipment" industry.

How does T2 Biosystems compare to SmileDirectClub?

T2 Biosystems (NASDAQ:TTOO) and SmileDirectClub (NASDAQ:SDCCQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

SmileDirectClub has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
SmileDirectClub N/A N/A N/A

T2 Biosystems has a beta of 7.71, indicating that its stock price is 671% more volatile than the broader market. Comparatively, SmileDirectClub has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled SmileDirectClub'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
SmileDirectClub Neutral

T2 Biosystems has higher earnings, but lower revenue than SmileDirectClub. T2 Biosystems is trading at a lower price-to-earnings ratio than SmileDirectClub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.01-$50.08M-$3.89N/A
SmileDirectClub$470.74M0.00-$86.40M-$0.29N/A

23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 0.1% of SmileDirectClub shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 64.7% of SmileDirectClub shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

SmileDirectClub beats T2 Biosystems on 6 of the 9 factors compared between the two stocks.

How does T2 Biosystems compare to G Medical Innovations?

T2 Biosystems (NASDAQ:TTOO) and G Medical Innovations (NASDAQ:GMVDF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

G Medical Innovations has lower revenue, but higher earnings than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.01-$50.08M-$3.89N/A
G Medical Innovations$4.42M0.00-$24.63MN/AN/A

T2 Biosystems has a beta of 7.71, meaning that its share price is 671% more volatile than the broader market. Comparatively, G Medical Innovations has a beta of 27.28, meaning that its share price is 2,628% more volatile than the broader market.

23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 6.0% of G Medical Innovations shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by company insiders. Comparatively, 37.1% of G Medical Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

G Medical Innovations has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
G Medical Innovations N/A N/A N/A

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled G Medical Innovations'average media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
G Medical Innovations Neutral

Summary

G Medical Innovations beats T2 Biosystems on 5 of the 7 factors compared between the two stocks.

How does T2 Biosystems compare to ViewRay?

T2 Biosystems (NASDAQ:TTOO) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

T2 Biosystems has a beta of 7.71, suggesting that its share price is 671% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
ViewRay N/A N/A N/A

In the previous week, ViewRay had 1 more articles in the media than T2 Biosystems. MarketBeat recorded 1 mentions for ViewRay and 0 mentions for T2 Biosystems. T2 Biosystems' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
ViewRay Neutral

T2 Biosystems has higher earnings, but lower revenue than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.01-$50.08M-$3.89N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Summary

ViewRay beats T2 Biosystems on 7 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to Acutus Medical?

T2 Biosystems (NASDAQ:TTOO) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

T2 Biosystems has a beta of 7.71, indicating that its stock price is 671% more volatile than the broader market. Comparatively, Acutus Medical has a beta of 5.67, indicating that its stock price is 467% more volatile than the broader market.

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
Acutus Medical -272.74%-311.64%-11.57%

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled Acutus Medical'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
Acutus Medical Neutral

T2 Biosystems has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.01-$50.08M-$3.89N/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 56.9% of Acutus Medical shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by insiders. Comparatively, 5.2% of Acutus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

T2 Biosystems beats Acutus Medical on 6 of the 11 factors compared between the two stocks.

How does T2 Biosystems compare to Minerva Surgical?

Minerva Surgical (NASDAQ:UTRS) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Minerva Surgical has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

In the previous week, Minerva Surgical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
T2 Biosystems Neutral

Minerva Surgical has a beta of 2.92, meaning that its stock price is 192% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.71, meaning that its stock price is 671% more volatile than the broader market.

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A
T2 Biosystems$7.68M0.01-$50.08M-$3.89N/A

23.2% of T2 Biosystems shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by company insiders. Comparatively, 0.0% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Minerva Surgical beats T2 Biosystems on 6 of the 9 factors compared between the two stocks.

Get T2 Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTOO vs. The Competition

Export
MetricT2 BiosystemsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$42K$46.05M$7.16B$12.48B
Dividend YieldN/A1.08%2.66%6.52%
P/E Ratio0.0020.7528.0224.70
Price / Sales0.0131.08540.3799.49
Price / CashN/A18.8649.2657.09
Price / Book0.008.4610.966.46
Net Income-$50.08M-$20.01M$3.57B$337.01M
7 Day PerformanceN/A4.17%2.12%1.69%
1 Month PerformanceN/A5.11%5.25%3.81%
1 Year PerformanceN/A-3.58%33.29%23.90%

T2 Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-98.6%$42K$7.68MN/A180
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/AN/AN/AN/A$26K$4.42MN/A72
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
AFIB
Acutus Medical
N/AN/AN/AN/A$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTOO) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel